- Home
- NWL vs VRDN Comparison
NWL vs VRDN Comparison
Compare NWL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NWL | VRDN |
|---|---|---|
| Founded | 1903 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NWL | VRDN |
|---|---|---|
| Price | $6.17 | $20.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $4.97 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 10.5M | 1.7M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $14,742,200,000.00 | $5,706,000.00 |
| Revenue This Year | $1.19 | $13.73 |
| Revenue Next Year | $1.58 | $279.00 |
| P/E Ratio | $37.41 | ★ N/A |
| Revenue Growth | ★ 11.14 | N/A |
| 52 Week Low | $3.07 | $13.18 |
| 52 Week High | $7.13 | $34.29 |
Technical Indicators
Market Signals| Indicator | NWL | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout NWL Newell Brands Inc.
Newell Brands Inc is an American consumer goods company with a portfolio of brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.